Get the Stockscreener App
46.84
0.83%
-0.39
Pre-market:
46.91
0.07
+0.15%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $46.84, with a volume of 15.85M.
It is down -0.83% in the last 24 hours and up +0.19% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$47.23
Open:
$47.31
24h Volume:
15.85M
Relative Volume:
1.12
Market Cap:
$101.69B
Revenue:
$47.64B
Net Income/Loss:
$5.42B
P/E Ratio:
17.54
EPS:
2.67
Net Cash Flow:
$13.09B
1W Performance:
-6.62%
1M Performance:
+0.19%
6M Performance:
-17.59%
1Y Performance:
+14.78%
1-Day Range:
$46.39
$47.37
1-Week Range:
$46.39
$50.74
52-Week Range:
$39.35
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
46.84 | 101.69B | 47.64B | 5.42B | 13.09B | 2.67 |
|
LLY
Lilly Eli Co
|
785.03 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
150.73 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
74.01 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
185.49 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.96 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol Myers Squibb (BMY) Collaborates on Alzheimer's Drug Deve - GuruFocus
Bristol-Myers (NYSE:BMY) Squibb Dividend Update Reflects Steady Healthcare NYSE Composite - Kalkine Media
Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Common and US$0.50 Preferred Dividends - Yahoo
BioNTech and Bristol Myers Squibb Collaborate on BNT327, a PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com
Bristol Myers Squibb to present positive new data on lymphoma treatment - Pharmafile
Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BM - GuruFocus
Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BMY Stock News - GuruFocus
Global Drugmakers Tap Chinese Biotech for Novel Cancer Therapies - Caixin Global
Bristol Myers Squibb declares quarterly dividend of $0.62 per share By Investing.com - Investing.com Nigeria
Bristol Myers Squibb Announces Dividend - marketscreener.com
Bristol-Myers Expands in Cancer Care With $1.35B OncoACP3 Deal - Insider Monkey
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Therapy - geneonline.com
Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress - MSN
Bristol Myers Squibb (BMY) Shares Cross 5% Yield Mark - Nasdaq
Myocardial Infarction Market Is Booming So Rapidly 2025-2032 - openPR.com
Vanguard Health Care Fund's Strategic Moves: A Closer Look at Bristol-Myers Squibb Co - Yahoo Finance
Bristol-Myers Squibb (BMY) Announces Positive Data From the Pivotal Phase 3 POETYK PsA-1 Trial - MSN
Bristol Myers Squibb (BMY) Achieves Strong Results with Breyanzi in Lymphoma Study - GuruFocus
Bristol Myers: positive phase 2 data in lymphoma - MarketScreener
Bristol Myers (BMY) Reports Promising Results from Lymphoma Stud - GuruFocus
Schizophrenia Drugs Market Size, Share & Forecast 2025 | Major - openPR.com
Bristol-Myers Squibb (BMY) Stock Analysis: Healthcare Giant with a 14.77% Potential Upside - DirectorsTalk Interviews
Business development leadership team - Bristol Myers Squibb
BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Treatment - geneonline.com
Rockland Trust Co. Sells 20,035 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Jim Cramer on Bristol Myers: “We Need to See That Stock Back Up at $60” - Insider Monkey
BioNTech and Bristol Myers Squibb Partner to Develop Bispecific Antibody Targeting PD-L1 and VEGF-A for Tumor Treatment - geneonline.com
Bristol-Myers Squibb’s SWOT analysis: stock outlook amid Cobenfy growth and pipeline potential - Investing.com
Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button' - Endpoints News
Bristol Myers (BMY) Showcases Promising New Data on Targeted Pro - GuruFocus
Bristol-Myers Promotes Attorney To Lead Corporate Affairs - Law360
BioNTech and Bristol Myers Squibb Partner to Develop BNT327 Antibody Targeting PD-L1 and VEGF-A Pathways in Tumors - geneonline.com
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu Compared with Placebo in Adults with Psoriatic Arthritis - marketscreener.com
Bristol-Myers stock holds steady as Cantor maintains neutral rating By Investing.com - Investing.com South Africa
BMY Reports Positive Data on Sotyktu From Arthritis Study - TradingView
Bristol Myers Squibb promotes Wendy Bartie to lead corporate affairs - PR Week UK
Bristol Myers: new data to be presented in hematology - marketscreener.com
Bristol-Myers stock holds steady as Cantor maintains neutral rating - Investing.com
Bristol Myers Squibb presents protein degradation data at EHA By Investing.com - Investing.com India
Bristol Myers Squibb presents protein degradation data at EHA - Investing.com
Bristol Myers Squibb Sets Q2 2025 Earnings Date: Key Financial Results Coming July 31 - Stock Titan
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025 - The Joplin Globe
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider - MSN
Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu - Yahoo Finance
Bristol Myers at Goldman Sachs Conference: Strategic Insights on Growth - Investing.com Australia
Bristol Myers bolsters radiopharma portfolio with PhiloChem deal - BioPharma Dive
Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
Bristol Myers (BMY) Sees Promising Results for Sotyktu in Phase 3 Trial - GuruFocus
BioNTech and Bristol Myers Squibb Collaborate on PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com
Bristol-Myers Squibb To Present At Goldman Sachs Global Conference; Webcast At 10:00 AM ET - Nasdaq
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bristol Myers Squibb Co Stock (BMY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hickey Benjamin | President, RayzeBio Org. |
May 09 '25 |
Sale |
38.01 |
97 |
3,702 |
0 |
| Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. |
Apr 25 '25 |
Buy |
47.58 |
4,250 |
202,215 |
83,513 |
| Shanahan Karin | EVP, Glob. Prod. Dev. & Supply |
Apr 01 '25 |
Option Exercise |
0.00 |
3,306 |
0 |
15,489 |
| Plenge Robert M | EVP, Chief Research Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
11,255 |
0 |
20,148 |
| Meyers Gregory Scott | EVP, Chief Digital & Tech Off. |
Mar 10 '25 |
Option Exercise |
0.00 |
23,150 |
0 |
26,937 |
| Shanahan Karin | EVP, Glob. Prod. Dev. & Supply |
Mar 10 '25 |
Option Exercise |
0.00 |
20,423 |
0 |
22,339 |
| Lenkowsky Adam | EVP, Chief Commercial Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
16,684 |
0 |
20,017 |
| Poole Ahn Amanda | EVP, Chief People Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
7,164 |
0 |
8,546 |
| LEUNG SANDRA | EVP, General Counsel |
Mar 10 '25 |
Option Exercise |
0.00 |
48,718 |
0 |
386,496 |
| Hoch Lynelle | President, Cell Therapy Org. |
Mar 10 '25 |
Option Exercise |
0.00 |
7,446 |
0 |
7,920 |
1.24%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):